[Establishment of a model for evaluating hypolipidemic effect in HepG2 cells]

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Dyslipidemia, characterized by abnormal lipid levels, is a major risk factor for cardiovascular diseases.
• Developing reliable in vitro models is crucial for efficient screening of potential hypolipidemic agents.
• Current methods for evaluating lipid-lowering effects often require complex in vivo studies.

Purpose of the Study:

• To establish and validate an in vitro model for assessing hypolipidemic effects.
• To create models for hypercholesterolemia and hypertriglyceridemia using HepG2 cells.
• To evaluate the efficacy of known lipid-lowering drugs within these models.

Main Methods:

• Hypercholesterolemia model: HepG2 cells cultured with cholesterol and 25-hydroxycholesterol.
• Hypertriglyceridemia model: HepG2 cells cultured with free fatty acids (e.g., oleic acid).
• Validation: Treatment with lovastatin (cholesterol-lowering) and fenofibrate (triglyceride-lowering) drugs, followed by measurement of cellular cholesterol, triglyceride, and related protein expression.

Main Results:

• Cholesterol-induced model showed increased cellular cholesterol and altered expression of HMG-CoA reductase, SREBP-2, and LDLR.
• Lovastatin treatment reduced cellular cholesterol and upregulated SREBP-2 and LDLR expression.
• Fenofibrate treatment increased free fatty acid absorption but did not elevate cellular triglyceride content, suggesting effective triglyceride modulation.

Conclusions:

• The developed in vitro models effectively simulate hypercholesterolemia and hypertriglyceridemia.
• These models provide a robust platform for screening and evaluating the hypolipidemic potential of various compounds.
• This approach facilitates the identification of novel agents for managing plasma lipid levels.